Pharmacological treatment of body dysmorphic disorder

Kevin Hong, Vera Nezgovorova, Genoveva Uzunova, Danya Schlussel, Eric Hollander

Research output: Contribution to journalReview article

Abstract

Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one’s physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.

Original languageEnglish (US)
Pages (from-to)697-702
Number of pages6
JournalCurrent Neuropharmacology
Volume17
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Body Dysmorphic Disorders
Pharmacology
Therapeutics
Transcranial Magnetic Stimulation
Major Depressive Disorder
Cognitive Therapy
Oxytocin
Antipsychotic Agents
Psychiatry
Psychology
Drug Therapy

Keywords

  • Antidepressants
  • Body dysmorphic disorder
  • Fluoxetine
  • Obsessive compulsive-related disorder
  • OCRD
  • SSRI
  • TMS

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Pharmacological treatment of body dysmorphic disorder. / Hong, Kevin; Nezgovorova, Vera; Uzunova, Genoveva; Schlussel, Danya; Hollander, Eric.

In: Current Neuropharmacology, Vol. 17, No. 8, 01.01.2019, p. 697-702.

Research output: Contribution to journalReview article

Hong, Kevin ; Nezgovorova, Vera ; Uzunova, Genoveva ; Schlussel, Danya ; Hollander, Eric. / Pharmacological treatment of body dysmorphic disorder. In: Current Neuropharmacology. 2019 ; Vol. 17, No. 8. pp. 697-702.
@article{d9240380396547d8b25d08a08badfd63,
title = "Pharmacological treatment of body dysmorphic disorder",
abstract = "Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one’s physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.",
keywords = "Antidepressants, Body dysmorphic disorder, Fluoxetine, Obsessive compulsive-related disorder, OCRD, SSRI, TMS",
author = "Kevin Hong and Vera Nezgovorova and Genoveva Uzunova and Danya Schlussel and Eric Hollander",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1570159X16666180426153940",
language = "English (US)",
volume = "17",
pages = "697--702",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Pharmacological treatment of body dysmorphic disorder

AU - Hong, Kevin

AU - Nezgovorova, Vera

AU - Uzunova, Genoveva

AU - Schlussel, Danya

AU - Hollander, Eric

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one’s physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.

AB - Body dysmorphic disorder is a challenging disorder that manifests as erroneously perceived flaws in one’s physical appearance and repetitive behaviors in response to appearance concerns. This disorder is also frequently comorbid with other psychiatric disorders, including major depressive disorder and autism spectrum disorder. It is currently understood to arise from a combination of biological, psychological, and environmental factors. Treatment of body dysmorphic disorder typically consists of a combination of pharmacotherapy and cognitive behavioral therapy. However, not all patients respond to treatment, and BDD symptoms remain even in those who do respond. This review outlines current pharmacological and neuromodulation treatments for body dysmorphic disorder and suggests directions for future studies of novel treatments such as augmentation with atypical antipsychotics and the use of intranasal oxytocin in cases of body dysmorphic disorder that show residual symptomatology even with tailored monotherapy. There is emerging evidence suggesting that non-invasive neurostimulatory techniques, such as repetitive transcranial magnetic stimulation, may be of value in treatment-resistant cases.

KW - Antidepressants

KW - Body dysmorphic disorder

KW - Fluoxetine

KW - Obsessive compulsive-related disorder

KW - OCRD

KW - SSRI

KW - TMS

UR - http://www.scopus.com/inward/record.url?scp=85070768461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070768461&partnerID=8YFLogxK

U2 - 10.2174/1570159X16666180426153940

DO - 10.2174/1570159X16666180426153940

M3 - Review article

C2 - 29701157

AN - SCOPUS:85070768461

VL - 17

SP - 697

EP - 702

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 8

ER -